Vaxart, Inc.
VXRTNext catalyst
VXA-CoV2-3.1
SARS-CoV2
Get an email about VXRT's next catalysts
Track Vaxart (VXRT) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
No other upcoming event in our data.
2 upcoming, 0 past
VXRT Reports Financial Results
Filed: 2026-11-05 AccNo: 0001437749-26-035275 Size: 272 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
SourceVXA-CoV2-3.1 Phase 2 Est. Readout
Primary completion for VXA-CoV2-3.1 trial (NCT06672055) in SARS-CoV2
SourceMarket Overview
Stock performance and key metrics
Vaxart, Inc. is an American biotechnology company focused on the discovery, development, and commercialization of oral recombinant vaccines administered using temperature-stable tablets that can be stored and shipped without refrigeration, eliminating the need for needle injection. Its development programs for oral vaccine delivery (Vector-Adjuvant-Antigen Standardized Technology known as VAAST) include prophylactic, enteric-coated tablet vaccines for inhibiting norovirus, seasonal influenza, respiratory syncytial virus, and human papillomavirus. It was founded in 2004 by Sean Tucker. Originally incorporated as West Coast Biologicals, Inc. in California in 2004, the company later changed its name to Vaxart, Inc. in July 2007, after reincorporating in Delaware. A significant development in the company's history was the reverse merger with Aviragen Therapeutics, Inc. on February 13, 2018, which led to Vaxart becoming a wholly owned subsidiary of Aviragen. Post-merger, the company continued as Vaxart, Inc.
WebsiteVXA-CoV2-3.1
SARS-CoV2
Open label Bivalent GII.4/GI.1 high dose vaccine 2×10 to the power
Norovirus Infections
VXA-A1.1
Influenza
AP611074
Condyloma
VXA-G1.1-NN
Norovirus Infections
Norovirus GI.1 Norwalk Virus Inoculum
Norovirus Infections
Bivalent GII.4/GI.1 high dose vaccine 2×10 to the power
Norovirus Infections
VXA-CoV2-3.3
SARS-CoV2
Bivalent GII.4/GI.1 medium dose vaccine 1×10 to the power
Norovirus Infections
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
VXA-CoV2-3.1 | Phase 2 | SARS-CoV2 | - | - |
Open label Bivalent GII.4/GI.1 high dose vaccine 2×10 to the power | Phase 2 | Norovirus Infections | - | - |
VXA-A1.1 | Phase 2 | Influenza | - | - |
AP611074 | Phase 2 | Condyloma | - | - |
VXA-G1.1-NN | Phase 2 | Norovirus Infections | - | - |
Norovirus GI.1 Norwalk Virus Inoculum | Phase 2 | Norovirus Infections | - | - |
Bivalent GII.4/GI.1 high dose vaccine 2×10 to the power | Phase 2 | Norovirus Infections | - | - |
VXA-CoV2-3.3 | Phase 2 | SARS-CoV2 | - | - |
Bivalent GII.4/GI.1 medium dose vaccine 1×10 to the power | Phase 2 | Norovirus Infections | - | - |
Frequently asked questions
What is in Vaxart, Inc.'s drug pipeline?→
CatalystAlert tracks 9 drug candidates in Vaxart, Inc.'s (VXRT) pipeline across Phase 2. Its lead program is VXA-CoV2-3.1 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Vaxart, Inc.'s next FDA catalyst?→
Vaxart, Inc.'s (VXRT) next tracked catalyst is a Phase 2 readout expected May 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track VXRT biotech catalysts?→
Add VXRT to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Vaxart, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.